MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13046-023-02649-6

Медицинская библиотека · Journal of experimental & clinical cancer research : CR · 2023

First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.

Cole Christopher B, Morelli Maria Pia, Fantini Massimo, Miettinen Markku, Fetsch Patricia, Peer Cody, Figg William D, Yin Tyler, Houston Nicole, McCoy Ann, Lipkowitz Stanley, Zimmer Alexandra, Lee Jung-Min, Pavelova Miroslava, Villanueva Erin N, Trewhitt Kathryn, Solarz B Brooke, Fergusson Maria, Mavroukakis Sharon A, Zaki Anjum, Tsang Kwong Y, Arlen Philip M, Annunziata Christina M

Клиническое исследование I фазыСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

NEO201 is a humanized IgG1 monoclonal antibody (mAb) generated against tumor-associated antigens from patients with colorectal cancer. NEO-201 binds to core 1 or extended core 1 O-glycans expressed by its target cells. Here, we present outcomes from a phase I trial of NEO-201 in patients with advanced solid tumors that have not responded to standard treatments.

METHODS

This was a single site, open label 3 + 3 dose escalation clinical trial. NEO-201 was administered intravenously every two weeks in a 28-day cycle at dose level (DL) 1 (1 mg/kg), DL 1.5 (1.5 mg/kg) and DL 2 (2 mg/kg) until dose limiting toxicity (DLT), disease progression, or patient withdrawal. Disease evaluations were conducted after every 2 cycles. The primary objective was to assess the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of NEO-201. The secondary objective was to assess the antitumor activity by RECIST v1.1. The exploratory objectives assessed pharmacokinetics and the effect of NEO-201 administration on immunologic parameters and their impact on clinical response.

RESULTS

Seventeen patients (11 colorectal, 4 pancreatic and 2 breast cancers) were enrolled; 2 patients withdrew after the first dose and were not evaluable for DLT. Twelve of the 15 patients evaluable for safety discontinued due to disease progression and 3 patients discontinued due to DLT (grade 4 febrile neutropenia [1 patient] and prolonged neutropenia [1 patient] at DL 2, and grade 3 prolonged (> 72 h) febrile neutropenia [1 patient] at DL 1.5). A total of 69 doses of NEO-201 were administered (range 1-15, median 4). Common (> 10%) grade 3/4 toxicities occurred as follows: neutropenia (26/69 doses, 17/17 patients), white blood cell decrease (16/69 doses, 12/17 patients), lymphocyte decrease (8/69 doses, 6/17 patients). Thirteen patients were evaluable for disease response; the best response was stable disease (SD) in 4 patients with colorectal cancer. Analysis of soluble factors in serum revealed that a high level of soluble MICA at baseline was correlated with a downregulation of NK cell activation markers and progressive disease. Unexpectedly, flow cytometry showed that NEO-201 also binds to circulating regulatory T cells and reduction of the quantities of these cells was observed especially in patients with SD.

CONCLUSIONS

NEO-201 was safe and well tolerated at the MTD of 1.5 mg/kg, with neutropenia being the most common adverse event. Furthermore, a reduction in the percentage of regulatory T cells following NEO-201 treatment supports our ongoing phase II clinical trial evaluating the efficiency of the combination of NEO-201 with the immune checkpoint inhibitor pembrolizumab in adults with treatment-resistant solid tumors.

TRIAL REGISTRATION: NCT03476681 . Registered 03/26/2018.

Для цитирования: Cole Christopher B, Morelli Maria Pia, Fantini Massimo, Miettinen Markku, Fetsch Patricia, Peer Cody, Figg William D, Yin Tyler, Houston Nicole, McCoy Ann, Lipkowitz Stanley, Zimmer Alexandra, Lee Jung-Min, Pavelova Miroslava, Villanueva Erin N, Trewhitt Kathryn, Solarz B Brooke, Fergusson Maria, Mavroukakis Sharon A, Zaki Anjum, Tsang Kwong Y, Arlen Philip M, Annunziata Christina M. First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.. Journal of experimental & clinical cancer research : CR. 2023. DOI: 10.1186/s13046-023-02649-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.